Aug 5, 2026 · 6 min
AI expectations split AMD and SpaceX as Lilly rides weight-loss demand
AMD Slides, SpaceX Falls, Eli Lilly Jumps as Obesity Drug Boom Shows No Sign of Slowing
The episode shows how investor expectations around artificial intelligence and GLP-1 drugs are producing sharply different outcomes across major companies.
- 1AMD’s sales outlook disappointed investors whose expectations had been lifted by the artificial-intelligence boom.
- 2SpaceX is directing substantial capital expenditure toward artificial intelligence, adding another dimension to its business risk.
- 3Eli Lilly raised its 2026 sales guidance as demand for its GLP-1 weight-loss drugs drove a major stock jump.
Don't miss
Eli Lilly’s stock jump after the company raised its 2026 sales guidance on booming demand for GLP-1 weight-loss drugs.
The brief
Stock Movers opens with a market snapshot before Kristine Aquino, Bloomberg’s managing editor for Markets Live, examines three sharply contrasting stock moves.
AMD’s sales outlook failed to satisfy elevated expectations tied to the artificial-intelligence boom, sending its shares lower despite the sector’s broader excitement.
SpaceX is also increasing capital expenditure on artificial intelligence, making its investment priorities part of the market conversation around the private aerospace company.
Eli Lilly moved in the opposite direction: booming demand for its GLP-1 weight-loss drugs prompted a higher 2026 sales outlook and a significant stock jump.
The episode’s central contrast is expectation management: AI enthusiasm can raise the bar for AMD, while obesity-drug demand is lifting Lilly’s guidance.
What was said on this episode
3 statements · 2 positive · 1 neutral
$101 billion of SpaceX stock will become available for trading Thursday.
“there's going to be 101 billion worth of space X stocks that's going to be available for trading on Thursday”
Listen at 2:46
Eli Lilly raised revenue guidance because demand for weight-loss and diabetes medicines exceeded expectations.
“They did boost their revenue guidance on the back of stronger than expected demand for for weight loss drugs and diabetes medicine.”
Listen at 3:24
Eli Lilly’s gains are lifting its sector among the S&P 500’s best performers.
“those gains in Eli Lilly definitely lifting the entire pharmaceutical, biotech and life sciences sector to one of the best performers on the S&P 500 today”
Listen at 3:43
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Mentioned
Advanced Micro Devices, Inc. (AMD)
GLP-1 receptor agonist
Artificial IntelligenceListen to the full episode and explore every guest, topic, and moment on PodLume.